These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 32333937)
1. 11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis. Gregory S; Hill D; Grey B; Ketelbey W; Miller T; Muniz-Terrera G; Ritchie CW Metabolism; 2020 Jul; 108():154246. PubMed ID: 32333937 [TBL] [Abstract][Full Text] [Related]
2. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning. Walker BR Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766 [TBL] [Abstract][Full Text] [Related]
3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Morton NM; Seckl JR Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901 [TBL] [Abstract][Full Text] [Related]
4. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056 [TBL] [Abstract][Full Text] [Related]
5. Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Scott JS; Goldberg FW; Turnbull AV J Med Chem; 2014 Jun; 57(11):4466-86. PubMed ID: 24294985 [TBL] [Abstract][Full Text] [Related]
6. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome. Masuzaki H; Flier JS Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456 [TBL] [Abstract][Full Text] [Related]
7. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Ge R; Huang Y; Liang G; Li X Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040 [TBL] [Abstract][Full Text] [Related]
8. 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome. Joharapurkar A; Dhanesha N; Shah G; Kharul R; Jain M Pharmacol Rep; 2012; 64(5):1055-65. PubMed ID: 23238463 [TBL] [Abstract][Full Text] [Related]
9. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome. Loerz C; Maser E J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040 [TBL] [Abstract][Full Text] [Related]
10. Inhibitors of 11beta-HSD1: a potential treatment for the metabolic syndrome. St Jean DJ; Wang M; Fotsch C Curr Top Med Chem; 2008; 8(17):1508-23. PubMed ID: 19075762 [TBL] [Abstract][Full Text] [Related]
11. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. Morgan SA; Tomlinson JW Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593 [TBL] [Abstract][Full Text] [Related]
12. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Stimson RH; Walker BR Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731 [TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye. Anderson S; Carreiro S; Quenzer T; Gale D; Xiang C; Gukasyan H; Lafontaine J; Cheng H; Krauss A; Prasanna G J Ocul Pharmacol Ther; 2009 Jun; 25(3):215-22. PubMed ID: 19456256 [TBL] [Abstract][Full Text] [Related]
14. A Novel Baum E; Zhang W; Li S; Cai Z; Holden D; Huang Y ACS Chem Neurosci; 2019 May; 10(5):2450-2458. PubMed ID: 30689943 [TBL] [Abstract][Full Text] [Related]
15. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. Cooper MS; Stewart PM J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Wamil M; Seckl JR Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Wang M Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570 [TBL] [Abstract][Full Text] [Related]
19. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101. Hong SP; Han D; Chang KH; Ahn SK Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297 [TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Stimson RH; Walker BR Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]